Download PDF
Horm Metab Res 2001; 33(2): 67-72
DOI: 10.1055/s-2001-12397
Original Basic

© Georg Thieme Verlag Stuttgart · New York

Stimulation of Arterial Smooth Muscle Cell Proliferation by Remnant Lipoprotein Particles Isolated by Immuno-Affinity Chromatography with Anti-apo A-I and Anti-apo B-100

A. Kawakami1 , A. Tanaka1 , T. Nakano2 , A. Saniabadi2 , F. Numano1
  • 1 Third Department of Internal Medicine, Tokyo Medical and Dental University, Tokyo, Japan
  • 2 Japan Immunoresearch Laboratories, Takasaki, Japan
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Postprandial lipidemia, characterized by high plasma triglyceride-rich lipoprotein remnants, is associated with atherosclerosis. It has also been known that proliferation of vascular smooth muscle cells is crucial for the development of atherosclerosis. In this study, we investigated the direct effect of remnant lipoprotein particles, which consist of chylomicron remnants and very low density lipoprotein remnants, on vascular smooth muscle cell proliferation. Blood was collected from six patients with postprandial lipidemia two hours after their usual meal. Remnant lipoprotein particles were isolated from plasma by immuno-affinity chromatography containing two monoclonal antibodies, anti-apo A-I (H-12) and anti-apo B-100 (JI-H). Remnant lipoprotein particles, as well as βVLDL, significantly stimulated the proliferation of porcine coronary artery smooth muscle cells in a concentration-dependent manner, whereas very low density lipoprotein (d < 1.006) was virtually ineffective. These observations are consistent with recent reports that triglyceride-rich lipoprotein remnants, which are rich in apo E as well, are atherogenic.

Key words:

Remnant Lipoprotein Particles - Triglyceride-Rich Lipoproteins - Postprandial Lipidemia - Apolipoprotein E - Smooth Muscle Cell Proliferation - Atherosclerosis

References

  • 1 Groot P H, Van Stiphout W AHJ, Krauss X H, Jansen H, van Tol A, van Ramhorst E, Chin-On S, Hofman A, Cresswell S R, Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease.  Arterioscler Thromb. 1991;  11 653-662
    PubMedGoogle Scholar
  • 2 Patsch J R, Meisenbock G, Hopferweiser T, Muhlberger V, Knapp E, Dunn J K, Gotto A M, Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state.  Arterioscler Thromb. 1992;  12 1336-1345
    CrossrefPubMedGoogle Scholar
  • 3 Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis.  Atherosclerosis. 1994;  106 83-97
    CrossrefPubMedGoogle Scholar
  • 4 Hodis H N. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis.  Circulation. 1999;  99 2858-2860
    PubMedGoogle Scholar
  • 5 Phillips N R, Waters D, Havel J R. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events.  Circulation. 1993;  88 2762-2770
    PubMedGoogle Scholar
  • 6 Tomono M, Kawazu S, Kato N. Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages.  J Atheroscl Thromb. 1994;  1 98-102
    PubMedGoogle Scholar
  • 7 Saniabadi A R, Umemura K, Shimoyama M, Adachi M, Nakano T, Nakajima K. Aggregation of human blood platelets by remnant like lipoprotein particles of plasma chylomicrons and very low density lipoproteins.  Thromb Haemost. 1997;  77 996-1001
    PubMedGoogle Scholar
  • 8 Campos E, Nakajima K, Tanaka A, Havel R J. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100.  J Lipid Res. 1992;  33 369-380
    PubMedGoogle Scholar
  • 9 Nakajima K, Saito T, Tamura A, Suzuki T, Nakano T, Adachi M, Tanaka A, Tada N. A new assay method for the quantification of cholesterol in remnant like lipoproteins in human serum using monoclonal anti apo B-100 and apo A-I immunoaffinity mixed gels.  Clin Chim Acta. 1993;  223 53-71
    CrossrefPubMedGoogle Scholar
  • 10 Lassel T S, Guerin M, Auboiron S, Chapman M J, Guy-Grand B. Preferential cholesteryl ester acceptors among triglyceride-rich lipoproteins during alimentary lipemia in normolipidemic subjects.  Arteroscler Thromb Vasc Biol. 1998;  18 65-74
    PubMedGoogle Scholar
  • 11 Kataoka S, Paidi M, Howard B V. Simplified isoelectric focusing/immunoblotting determination of apolipoprotein E phenotype.  Clin Chem Acta. 1994;  40 11-13
    PubMedGoogle Scholar
  • 12 Mahley R W, Innerarity T L, Rall S C Jr, Weisgraber K H. Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia.  Ann N Y Acad Sci. 1985;  454 209-221
    PubMedGoogle Scholar
  • 13 Havel R J, Eder H A, Bragdon J H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.  J Clin Invest. 1955;  34 1345-1353
    CrossrefPubMedGoogle Scholar
  • 14 Lowry O H, Rosebrough N J, Farr A L, Randall R J. Protein measurement with the Folin phenol reagent.  J Biol Chem. 1951;  193 265-275
    PubMedGoogle Scholar
  • 15 Kitamura T, Ito S, Kato Y, Sasamoto K, Okazaki M. Analysis of serum lipoproteins by high performance gel filtration chromatography.  J Jpn Anal Chem. 1996;  41 103-106
    PubMedGoogle Scholar
  • 16 Ishiyama M, Shiga M, Sasamoto K, Mizoguchi M, Pin-gang H. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye.  Chem Pharm Bull. 1993;  41 1118-1122
    CrossrefPubMedGoogle Scholar
  • 17 Magaud J P, Sargent I, Mason D Y. Detection of human white cell proliferative responses by immunoenzymatic measurement of bromodeoxyuridine uptake.  J Immunol Methods. 1988;  106 95-100
    CrossrefPubMedGoogle Scholar
  • 18 Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma.  Biochem med. 1976;  15 212-216
    CrossrefPubMedGoogle Scholar
  • 19 Zilversmit D B. Atherogenesis: a postprandial phenomenon.  Circulation. 1979;  60 473-480
    CrossrefPubMedGoogle Scholar
  • 20 Simons L A, Dwyer T, Simons J, Bernstein L, Mock P, Poonia N S, Balasubramaniam S, Baron D, Branson J, Morgan J, Roy P. Chylomicrons and chylomicron remnants in coronary artery disease: a case control study.  Atherosclerosis. 1987;  65 181-189
    PubMedGoogle Scholar
  • 21 Havel R J. Mc Collum Ward Lecture. Triglyceride rich lipoproteins and atherosclerosis-new prospectives.  Am J Clin Nutr. 1993;  59 795-799
    PubMedGoogle Scholar
  • 22 Havel R J, Rapaport E. Management of primary hyperlipidaemia.  N Engl J Med. 1995;  332 1491-1498
    CrossrefPubMedGoogle Scholar
  • 23 Zilversmit D B. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins.  Clin Chem Acta. 1995;  41 153-158
    PubMedGoogle Scholar
  • 24 Sehayek E, Lewin-Velvert U, Chajek-Shaul T, Eisenberg S. Lipolysis exposes unreactive endogenous apolipoprotein E-3 in human and rat plasma very low density lipoprotein.  J Clin Invest. 1991;  88 553-560
    PubMedGoogle Scholar
  • 25 Shi A H, Yoshinari M, Wakisaka M, Iwase M, Fujishima M. Lysophosphatidylcholine molecular species in low density lipoprotein of type 2 diabetes.  Horm Metab Res. 1999;  31 283-286
    PubMedGoogle Scholar
  • 26 Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, Tsunoda R, Sakamoto T, Nakato T, Nakajima K, Ogawa H, Sugiyama S, Yoshimura M, Yasue H. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease.  Circulation. 1999;  99 2858-2860
    PubMedGoogle Scholar
  • 27 Inoue T, Saniabadi A R, Matsunaga R. Impaired endothelium-dependent acetylcholine-induced coronary artery relaxation in patients with high serum remnant lipoprotein particles.  Atherosclerosis. 1998;  139 363-367
    CrossrefPubMedGoogle Scholar
  • 28 Takeichi S, Nakajima Y, Osawa M, Yukawa N, Saito T, Seto Y, Nakano T, Adachi M, Jitsukata K, Horiuchi K, Wang T, Nakajima K. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death.  Atherosclerosis. 1999;  142 309-315
    CrossrefPubMedGoogle Scholar
  • 29 Rapp J H, Lespine A, Hamilton R L, Colyvas N, Chaumeton A H, Tweedie-Hardman J, Kotite L, Kunitake S T, Harvel R J, Kane J P. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque.  Arterioscler Thromb. 1994;  14 1767-1774
    PubMedGoogle Scholar
  • 30 Saniabadi A R, Umemura K, Suzuki Y, Kondo K, Ikeda Y, Adachi M, Nakashima M. Adenosine 5’-diphosphate as a factor in platelet aggregation induced by human plasma remnant lipoproteins.  Life Sci. 1998;  63 1065-1074
    CrossrefPubMedGoogle Scholar
  • 31 Mahley R W. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology.  Science. 1988;  240 622-630
    PubMedGoogle Scholar
  • 32 Riddell D, Graham A, Owen J. Apolipoprotein E inhibits platelet aggregation through the L-arginine: Nitric oxide pathway.  J Biol Chem. 1997;  272 89-95
    CrossrefPubMedGoogle Scholar
  • 33 van Dijk K W, van Vlijmen B J, van’t Hof H B, van der Zee A, Santamarina-Fojo S, van Berkel T J, Havekes L M, Hofker M H. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apo E but is inhibited by excess apo E.  J Lipid Res. 1999;  2 336-344
    PubMedGoogle Scholar
  • 34 Ismail N A, Alavi M Z, Moore S. Lipoprotein-proteoglycan complexes from injured rabbit aortas accelerate lipoprotein uptake by arterial smooth muscle cells.  Atherosclerosis. 1994;  105 79-87
    CrossrefPubMedGoogle Scholar
  • 35 Ji Z S, Brecht W J, Miranda R D, Hussain M M, Innerarity T L, Mahley R W. Role of heparan sulphate proteoglycans in the binding and uptake of apolipoprotein E enriched remnant lipoproteins by cultured cells.  J Biol Chem. 1993;  268 10 160-10 167
    PubMedGoogle Scholar

A. Tanaka

The Third Department of Internal Medicine
Tokyo Medical and Dental University

1-5-45 Yushima, Bunkyo-ku
113 - 8519 Tokyo
Japan


Phone: Phone:+ 81-3-5803-5231

Fax: Fax:+ 81-3-5803-0133

Email: E-mail:tanaka.med3@tmd.ac.jp

      >